Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. Show more
Location: 1185 Avenue of the Americas, New York, NY, 10036, United States | Website: https://www.oramed.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
87.83M
52 Wk Range
$1.82 - $3.09
Previous Close
$2.15
Open
$2.15
Volume
149,028
Day Range
$2.11 - $2.25
Enterprise Value
-43.43M
Cash
130.6M
Avg Qtr Burn
-2.614M
Insider Ownership
13.58%
Institutional Own.
19.11%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORMD-0801 (ORA-D-013-1) Details Diabetes, Type 2 diabetes | Phase 3 Update | |
ORMD-0801 Details Non-alcoholic steatohepatitis , Liver disease | Phase 2 Update |